CAG heads into late April with short sellers rebuilding positions, the analyst community in retreat, and board insiders stepping in to buy the dip — a rare three-way divergence on a stock trading near multi-year lows.
Short interest is the most pressing story. At nearly 9% of the free float — 8.96% as of April 28 — short positioning is at the high end of where it has been all month. The one-month increase is steep: shorts grew by 34% over the past 30 days, rising from around the 8.2% range in late March to the current level. The trajectory shifted sharply around April 9-10, when shorts accelerated from roughly 8.1% to 9.1% within a week. That move has since partially consolidated, with the weekly change now essentially flat (-0.5%), but the overall stock of shorts remains elevated. Days to cover checks in at 1.47, so there is no meaningful squeeze dynamic — this is not a forced-covering setup; bears are positioned and comfortable.
The lending market is not putting pressure on those shorts. Availability remains very loose. Cost to borrow runs at just 0.45% — barely above the rate for easy-to-borrow names — and that rate has barely moved, up only 2.3% on the week. The borrow is cheap, access is easy, and nothing in the lending structure signals imminent squeeze risk. Options positioning echoes that lack of urgency. The put/call ratio is 0.70, almost exactly in line with its 20-day average of 0.68 and carrying a z-score of just 0.18. Options traders are neither notably bearish nor rushing for cover. Overall, positioning looks aggressive on the short side in terms of size, but not frantic in terms of borrow or hedging demand.
The Street has spent most of April cutting. The direction of travel from analysts is almost uniformly downward. Morgan Stanley lowered its target to $15 from $17 on April 23 while maintaining its Equal-Weight view. Stifel made an identical cut on April 21, also holding at Hold. Both moves came after a wave of target reductions on April 2 — Goldman Sachs, RBC Capital, Barclays, and Morgan Stanley all reduced targets that day, mostly in the $17-18 range, following Conagra's last earnings print. BNP Paribas downgraded the stock outright on April 9, cutting from Outperform to Neutral and dropping its target to $16. BTIG initiated coverage at Neutral on April 14 without a price target, adding another neutral voice to the chorus. The mean price target now stands at $16.22, implying 14% upside from the current $14.23 close — but that gap has been created by a falling stock, not an improving fundamental view. The bear case points to a downside scenario around $13; the bull case acknowledges margin pressure in FY26 but points to potential long-term recovery if volume trends improve. The RSI at 34 confirms the stock is deep into oversold territory. A P/E of 8.4x and P/B below 0.80 reflect how aggressively the market has re-rated the stock — P/B has fallen more than 12% over the past month alone.
Against that backdrop, two board-level insiders stepped in to buy. Chairman Richard Lenny purchased 25,000 shares at $14.34 on April 14, committing $358,500. Director John Mulligan added 17,500 shares at roughly the same price, for just over $250,000. Net insider buying over the past 90 days totals approximately $609,000 in value. These are not trivial buys at the margin — Lenny's purchase in particular carries the weight of the chair seat. Neither buy triggers a significance score above 3, but the clustering and timing, coming in the same session near recent lows, is notable. Blackrock also added more than 3.1 million shares in its most recent filing to March 31, and Dimensional Fund Advisors added nearly 3 million shares — two of the largest holders increasing at a time when the stock has been under sustained pressure.
Conagra's next earnings event is scheduled for July 9, giving the market roughly 10 weeks to judge whether the volume recovery narrative gains any traction. The key tension to watch between now and then is whether the short position at 9% of the float consolidates further — especially if the macroeconomic environment for packaged food names remains challenged — or whether the insider and institutional buying signals any re-rating catalyst ahead of the Q3 print.
See the live data behind this article on ORTEX.
Open CAG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
